Machine intelligence and big data analyst firm CB Insights has put together a list of what it considers to be today’s 150 “most promising” private digital health startups. Leuven-based brain imaging AI leader icometrix made the list.
CB Insights today named icometrix to the inaugural Digital Health 150 ranking, showcasing the 150 most promising private digital health companies in the world. CB Insights CEO Anand Sanwal revealed the final Digital Health 150 during Future of Health, a gathering of top executives across some of the largest healthcare institutions, startups, and investment firms.
icometrix' CE-marked and FDA-cleared icobrain software, extracts clinically meaningful information from brain MRI and CT scans of patients with neurological disorders, such as multiple sclerosis, Alzheimer's disease, dementia, and brain trauma. The icobrain AI solutions are already used in more than 120 hospitals and imaging center networks worldwide, and in clinical studies by 4 out of the top 5 pharmaceutical companies.
"From pharmaceuticals to patient care, technology is rapidly changing healthcare, and The Digital Health 150 showcases the 150 best startups spearheading innovation and change in the sector," said CB Insights CEO Anand Sanwal. "It's a privilege to use CB Insights' data to identify and shine a light on these companies, and we look forward to tracking their success in 2019 and beyond."
"We are honored to receive this recognition by CB Insights," said Prof. Wim Van Hecke, CEO of icometrix. "Innovative digital health solutions are changing healthcare at a rapid pace. Through our brain MRI and CT measures, we help radiologists, neurologists, and neurosurgeons to make more informed and more accurate decisions for patients with neurological disorders. As many neurological diseases are chronic, it is crucial to provide individual patients with the right treatment at the right moment," Prof. Van Hecke concludes.
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, measures the overall health and growth potential of private companies to help predict a company's momentum.
Icometrix was founded in 2011 as a spin-off company of the universities and university hospitals of Leuven and Antwerp. Today, icometrix has grown to a team of over 30 people and is internationally active with headquarters in Leuven and an office in Boston, USA.
Icometrix developed icobrain, which offers radiologists & neurologists a fully automated software for follow-up of people with Multiple sclerosis. This by measuring evolution of brain volume changes and FLAIR white matter hyper intensities. icobrain is easy to integrate in your workflow and allows you to reduce scan- and reporting times.
The icometrix team also acts as an image analysis expert in clinical trials and research studies. Imaging biomarker outcomes often serve as the primary endpoints in clinical trials. This way the software-as-a-service is incorporated in clinical trials and large research studies regarding Traumatic Brain Injury (TBI), Epilepsy, Alzheimer’s Disease, Stroke, etc.
Source: Icometrix, Leuven MindGate